Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics Inc. (ADMA) is a commercial-stage biopharmaceutical company advancing plasma-derived therapies for immune deficiencies and infectious diseases. This dedicated news hub provides verified updates on corporate developments, regulatory milestones, and clinical progress.
Investors and healthcare professionals will discover timely coverage of earnings announcements, FDA decisions, manufacturing innovations, and strategic partnerships. Our curated selection emphasizes ADMA’s operational achievements in plasma collection, biomanufacturing excellence, and therapeutic pipeline advancements.
Key updates include product authorization progress, financial disclosures, patent developments, and peer-reviewed research findings. All content undergoes rigorous verification to ensure accuracy for investment and industry analysis.
Bookmark this page for direct access to ADMA’s official communications and expertly contextualized news. Maintain awareness of critical developments impacting this innovative biologics manufacturer through Stock Titan’s trusted reporting.
ADMA Biologics, Inc. (Nasdaq: ADMA) announced its intention to conduct an underwritten public offering of common stock. The company aims to grant underwriters a 30-day option to purchase an additional 15% of the shares. Proceeds from the offering will be used to advance commercial sales of FDA-approved products, expand the plasma collection facility network, scale manufacturing capacity, explore business development opportunities, and for general corporate purposes. The offering is subject to market conditions and is filed under a shelf registration statement with the SEC.
ADMA Biologics (ADMA) announced a poster presentation at the virtual 2021 ISIRV-WHO Conference on October 19-22. The poster details the clinical impact of ASCENIV™, a novel intravenous immune globulin, as a concomitant therapy for a patient with severe respiratory viral disease and COVID-19. ASCENIV, approved by the FDA in April 2019, treats primary humoral immunodeficiency (PI). ADMA manufactures and markets three FDA-approved plasma-derived biologics, focusing on immunocompromised patients and infectious diseases.
ADMA Biologics announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon brings over a decade of experience in corporate finance and strategic advising within the life sciences industry. His previous roles include C-suite positions and leading a $6.5 billion acquisition at Momenta Pharmaceuticals. Chairman Steven Elms emphasized Dr. Kwon's strategic insights as crucial for ADMA's revenue growth in its immunoglobulin product line. Dr. Kwon expressed his commitment to enhancing shareholder value by maximizing the potential of ADMA's biologics manufacturing platform.
ADMA Biologics, Inc. (Nasdaq: ADMA) has announced on-demand access to an educational event at IDWeek 2021 focused on respiratory viral infections. Renowned experts Dr. Michael Ison and Dr. Jolan Walter highlighted the benefits of ASCENIV™, an intravenous immunoglobulin product, in treating pediatric patients with primary immunodeficiency and RSV. The presentation included two illustrative cases demonstrating ASCENIV's efficacy. Approved by the FDA in April 2019, ASCENIV is designed for treating primary humoral immunodeficiency and is backed by proprietary manufacturing methods.
ADMA Biologics has announced an exclusive educational event at IDWeek 2021, focusing on respiratory viral infections, including RSV. The event features expert discussions by Dr. Michael Ison and Dr. Jolan Walter addressing key clinical challenges and introducing ASCENIV™, a novel intravenous immunoglobulin. ASCENIV is FDA-approved for treating primary immune deficiency and is manufactured using a unique plasma donor screening methodology. The session will occur on October 1, 2021, from 1:00 PM to 1:45 PM ET at the IDWeek Learning Lounge.
ADMA Biologics (Nasdaq: ADMA) will participate in a virtual fireside chat at the Cantor Healthcare Conference on September 30, 2021, at 9:20 a.m. ET. Adam Grossman, President and CEO, will lead the discussion. A webcast of the event will be available on the company’s website and archived for 90 days. ADMA specializes in the manufacturing and marketing of plasma-derived biologics, currently offering three FDA-approved products for immunodeficient patients and those at risk of infectious diseases. The company operates an FDA-licensed facility in Boca Raton, Florida.
ADMA Biologics has received FDA approval for its in-house aseptic fill-finish machine, the VanRx SA25, marking a pivotal development in its supply chain strategy. This approval allows ADMA to handle internal fill-finish operations, improving gross margins, patient supply consistency, and reducing production cycle times. The VanRx's advanced design enhances operational control and visibility over product releases. Additionally, the approval opens doors for new contract manufacturing opportunities, positioning ADMA to potentially exceed its financial targets and sustain revenue growth.
ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 12:30 p.m. ET. A webcast of this event will be available on ADMA's website and will be archived for 90 days following the event. ADMA specializes in developing plasma-derived biologics aimed at treating immunodeficient patients and is known for FDA-approved products such as BIVIGAM®, ASCENIV™, and NABI-HB®.
ADMA Biologics, Inc. has received FDA approval for its ADMA BioCenters plasma collection facility in Maryville, Tennessee, enhancing its ability to collect human source plasma. This facility started operations in Q4 2020 and is now licensed to introduce plasma into interstate commerce. With a goal of operating 10+ FDA-approved centers by 2024, ADMA aims to secure plasma supply and control manufacturing operations. The center is equipped with advanced technology and aims to employ 50 staff at full capacity, while offering new donors competitive compensation for contributions.
ADMA Biologics reported a record total revenue of $17.8 million for Q2 2021, marking a 129% increase year-over-year, driven primarily by its intravenous immune globulin (IVIG) product portfolio. The company anticipates reaching an annualized revenue run rate of approximately $100 million by the end of 2021. Despite a net loss of $18.9 million for the quarter, improvements in revenue and gross margins were noted. Strategic initiatives, including an expanded production capacity and supply chain enhancements, position ADMA for continued growth and operational efficiencies in the future.